Clinical Trial Update: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SI-B001 in combination with irinotecan for recurrent metastatic esophageal squamous cell carcinoma. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Irinotecan (Irinotecan)
• SI-B001

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Esophageal Squamous Cell Carcinomas | Phase 2 | Status: ACTIVE_NOT_RECRUITING